{"filings":[{"id":3429796,"accession_number":"0001213900-26-109016","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-10-13T20:00:30+00:00","items":["5.02","9.01"],"status":"ready","headline":"Niki BioSolutions names Thomas Freeburg CFO with $250K salary, 50,000 options at $8.83","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Thomas Freeburg, 59, as CFO on Oct 9, 2026; two-year term commencing Sept 1, 2026, reporting to CEO Ian Huen.","Base salary $250,000, with $25,000 deferred until the company raises $3M cumulatively; rises to $275,000 at $5M raised; bonus up to 50% of salary.","Receives 50,000 stock options at an $8.83 exercise price under the Niki BioSolutions 2026 Equity Incentive Plan; 20 days PTO and $150/month tech allowance.","Qualifying termination severance: lump sum of remaining base salary through end of Initial Term or six months, whichever is greater, plus COBRA and full unvested equity acceleration.","Freeburg was CFO/Secretary/Treasurer of Interpace Biosciences (IDXG) from Feb 2021 to Mar 2023, with earlier SEC reporting roles at Tapestry (TPR) and Scholastic (SCHL)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3375796,"accession_number":"0001213900-26-108572","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-10-09T21:12:08+00:00","items":["1.01","9.01"],"status":"ready","headline":"Niki BioSolutions signs ATM sales agreement with H.C. Wainwright for up to $1,396,000 of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement dated October 9, 2026 lets Niki BioSolutions (NIKI) sell up to $1,396,000 of common stock through H.C. Wainwright as sales agent or principal.","Wainwright earns a 3.0% placement fee on gross sales as agent; Brookline Capital Markets acts as qualified independent underwriter for no additional compensation.","Director and largest shareholder Dr. Kira Sheinerman is a Wainwright managing director, creating a FINRA Rule 5121 conflict; Wainwright cannot sell to discretionary accounts without written approval.","Offering falls under a Form S-3 shelf (File No. 333-298608) declared effective October 9, 2026; exhibits include the Sales Agreement (1.1) and Hunter Taubman Fischer & Li opinion (5.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2852678,"accession_number":"0001213900-26-099695","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-09-14T20:00:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Niki BioSolutions files corporate presentation for H.C. Wainwright conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation led by President & COO Alidad Mireskandari, Ph.D. at H.C. Wainwright Global Investment Conference, September 2026.","Provided excerpt contains only a cover page; no financial figures, guidance, or operational updates are disclosed in the filing.","Company trades on Nasdaq Capital Market under ticker NIKI; formerly known as Aptorum Group Limited.","No substantive new information beyond the presentation's existence; investors should refer to full exhibit for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2686436,"accession_number":"0001213900-26-097705","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-09-04T20:31:51+00:00","items":["5.02","9.01"],"status":"ready","headline":"Niki BioSolutions names Ian Huen CEO/Chairman and Alidad Mireskandari President/COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Huen appointed CEO and Chairman effective Aug 1, 2026; 6-month initial term, HKD 210,000/month (~USD 26,800).","Alidad Mireskandari named President and COO; annual base salary $320,000, rising to $350,000 if $5M capital raised.","Mireskandari receives 20,000 RSUs vesting at merger close and options for 800,000 shares under 2026 Equity Incentive Plan.","Appointments follow July 22, 2026 merger where Niki acquired DiamiR Biosciences; Mireskandari was DiamiR's prior CEO.","Mireskandari severance: 6 months' base salary, increasing to 12 months as of Jan 1, 2027; 2-year initial term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2412038,"accession_number":"0001213900-26-092689","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K/A","filed_at":"2026-08-21T21:17:44+00:00","items":["9.01"],"status":"ready","headline":"Niki BioSolutions closes DiamiR merger; acquired firm posts FY2026 net loss and going-concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 20, 2026; DiamiR Biosciences became a wholly-owned subsidiary of Niki BioSolutions (formerly Aptorum Group).","DiamiR FY2026 net loss of $659,936 vs $743,235 in FY2025; revenue grew to $190,355 from $631,729.","Auditor cites significant working capital deficiency and needs to raise funds; going-concern doubt raised.","As of May 31, 2026, DiamiR had cash of $112,690, current assets $345,250 and current liabilities $2,191,803.","DiamiR's outstanding convertible notes are expected to convert to Niki common shares under the merger agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2411678,"accession_number":"0001213900-26-092661","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-08-21T21:00:33+00:00","items":["9.01"],"status":"ready","headline":"Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.","Cash fell to $1,834,171 from $3,452,891 at Dec 31, 2025; operating cash outflow of $1,553,720.","Management disclosed substantial doubt about going concern within next 12 months; negative working capital of $2,475,418.","R&D expenses rose to $383,752 from $19,375 in H1 2025; related-party convertible notes total $3,508,500.","1-for-10 reverse stock split effective July 20, 2026; 1,979,216 shares issued to DiamiR stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2132796,"accession_number":"0001213900-26-086639","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-08-07T20:00:46+00:00","items":["8.01"],"status":"ready","headline":"Niki BioSolutions regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on March 5, 2026 for bid price below $1.00 for 30 consecutive business days.","On August 4, 2026, Nasdaq confirmed compliance as closing bid price was $1.00+ for 10 consecutive days (July 21-Aug 3, 2026).","Listing matter now closed; company avoids delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1730676,"accession_number":"0001213900-26-079416","cik":1734005,"company_name":"Aptorum Group Ltd","ticker":"APM","form_type":"8-K","filed_at":"2026-07-20T12:15:22+00:00","items":["2.01","3.03","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Aptorum completes merger with DiamiR, redomiciles as Niki BioSolutions, trades under NIKI","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 20, 2026; Aptorum redomiciled to Delaware and renamed Niki BioSolutions, Inc.","DiamiR shareholders received ~1.98M shares of Niki common; Aptorum shareholders got ~814K common and ~180K Series A preferred.","1-for-10 reverse stock split effective July 20, reducing outstanding Class A from ~6.35M to ~635K shares.","New board: Ian Huen (Chairman), Kira Sheinerman, Justin Wu, Douglas Arner, Laura A. Philips, Alidad Mireskandari (observer).","Adopted 2026 Incentive Plan reserving 4.5M shares plus annual evergreen increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}